The MPO Study: Just a European HEMO Study or Something Very Different?

摘要: Although results from observational and epidemiological studies suggested a survival benefit associated with high-flux hemodialysis, conclusive evidence prospective randomized clinical trials has been lacking. Both the HEMO Study in USA Membrane Permeability Outcome (MPO Study) Europe are investigating effect of high- low-flux hemodialysis on patient outcomes, even though there were some significant differences design two studies. An earlier trial could not show between groups being treated membranes different material permeability, but this was designed specifically to examine particular endpoint. Based these previous experiences, MPO addressed population which considered be more susceptible intervention dialysis. To identify patients an elevated risk, low serum albumin levels chosen as indicator; is malnutrition, inflammation, atherosclerosis, increased risk morbidity mortality. Together albumin, had new dialysis selected for Study. These considerations selection, together additional methodological refinements study allow conclusion that valid its own rather than European version